Adverum Biotechnologies Inc [ADVM] stock is trading at $3.23, up 12.15%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ADVM shares have gain 9.12% over the last week, with a monthly amount drifted -29.93%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Adverum Biotechnologies Inc [NASDAQ: ADVM] stock has seen the most recent analyst activity on June 25, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $25. Previously, H.C. Wainwright started tracking the stock with Buy rating on April 30, 2024, and set its price target to $30. On July 07, 2022, upgrade upgraded it’s rating to Buy but maintained its price target of $4 on the stock. Cantor Fitzgerald downgraded its rating to a Neutral. SVB Leerink downgraded its rating to a Mkt Perform but $5 remained the price target by the analyst firm on May 03, 2021. Truist downgraded its rating to Hold for this stock on April 29, 2021, and downed its price target to $9. In a note dated April 29, 2021, RBC Capital Mkts downgraded an Sector Perform rating on this stock but restated the target price of $6.
Adverum Biotechnologies Inc [ADVM] stock has fluctuated between $2.64 and $10.98 over the past year. Currently, Wall Street analysts expect the stock to reach $10 within the next 12 months. Adverum Biotechnologies Inc [NASDAQ: ADVM] shares were valued at $3.23 at the most recent close of the market. An investor can expect a potential return of 209.6% based on the average ADVM price forecast.
Analyzing the ADVM fundamentals
Gross Profit Margin for this corporation currently stands at -12.49% with Operating Profit Margin at -150.16%, Pretax Profit Margin comes in at -130.93%, and Net Profit Margin reading is -130.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.73, Equity is -0.93 and Total Capital is -0.96. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.3.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.92 points at the first support level, and at 2.61 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.41, and for the 2nd resistance point, it is at 3.59.
Ratios To Look Out For
For context, Adverum Biotechnologies Inc’s Current Ratio is 5.73. Further, the Quick Ratio stands at 5.73, while the Cash Ratio is 2.65. Considering the valuation of this stock, the price to sales ratio is 67.47, the price to book ratio is 0.95.
Transactions by insiders
Recent insider trading involved Leonard Braden Michael, 10% Owner, that happened on Mar 26 ’25 when 20407.0 shares were purchased. 10% Owner, Leonard Braden Michael completed a deal on Mar 27 ’25 to buy 16593.0 shares. Meanwhile, 10% Owner Leonard Braden Michael bought 0.3 million shares on Apr 22 ’25.
